Complement Factor C1s Inhibitors for Synapse Loss Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aberrant activation or insufficient regulation of the complement cascade contributes to numerous diseases and pathological conditions, including neurodegenerative diseases, where premature synapse loss leads to cognitive decline, and there is a need to inhibit or modulate the aberrant activity of complement factors.
Innovation Solution
Development of compounds represented by specific chemical formulas that inhibit or modulate the activity of complement factors, particularly C1s, to prevent synapse loss and slow down the progression of neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the complement cascade is activated to clear pathogens, then immune defense is improved, but tissue damage and cell destruction occur
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to modulate complement factor activity. These compounds bind to complement factors (C1s, C3, C5) and regulate their activation, preventing uncontrolled complement cascade that leads to tissue damage while maintaining necessary immune defense functions.
Solution Approach 2:
The invention changes the activation state parameter of complement factors through pharmacological intervention. By administering complement inhibitors, the system shifts complement activity from an overactivated harmful state to a regulated protective state, reducing tissue damage while preserving immune function.
2Productivity
If C1s activity is increased to enhance complement activation, then pathogen clearance is improved, but synapse loss and neurodegeneration are accelerated
Solution Approach 1:
Small molecule compounds serve as intermediaries that specifically bind to C1s and modulate its protease activity. This regulation prevents excessive synapse pruning in the brain while maintaining sufficient C1s activity for pathogen clearance in peripheral tissues, achieving spatially selective control.
Solution Approach 2:
The patent applies local quality control by using compounds that can selectively inhibit C1s activity in specific tissues (e.g., brain) while allowing normal function elsewhere. This enables differential regulation of complement activity in different anatomical locations to prevent neurodegeneration without compromising immune defense.
3Reliability
If complement factors are accumulated to strengthen immune response, then pathogen elimination is improved, but disease pathology is worsened
Solution Approach 1:
The patent implements feedback control mechanisms where complement inhibitors monitor and regulate complement factor accumulation. When complement activation reaches harmful levels, the inhibitors bind to complement factors and reduce their activity, creating a negative feedback loop that prevents disease pathology while maintaining effective immune response.
Data Source
AI summary
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.